At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 127 enrolled
Drug / intervention
Mometasone Furoate Nasal Spray (MFNS) +1 moredrug
Likely dose
Mometasone Furoate Nasal Spray (MFNS) 100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old
In Brief
A Phase 3 clinical trial evaluating Mometasone Furoate Nasal Spray (MFNS) and Placebo nasal spray for Nasal Polyps. Completed, enrolled 127 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of Nasonex® (Mometasone Furoate Nasal Spray(MFNS)) in the treatment of nasal polyps in pediatric subjects between the ages of 6 and less than 18 years old. Safety will be the primary focus of this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasal Polyps
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedSep 2006
Primary CompletionJun 2008
TodayJul 2026
First PostedSep 20, 2006
Enrollment StartJul 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.8 years ago
Interventions
Mometasone Furoate Nasal Spray (MFNS)drug
100 mcg nasal spray
Placebo nasal spraydrug
One spray of placebo nasal spray in each nostril once daily for 4 months.